Compare CNXU & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNXU | EIC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 228.8M |
| IPO Year | 2025 | 2018 |
| Metric | CNXU | EIC |
|---|---|---|
| Price | $8.89 | $10.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.63 |
| AVG Volume (30 Days) | ★ 176.1K | 87.7K |
| Earning Date | N/A | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.85 | $9.17 |
| 52 Week High | $13.66 | $13.92 |
| Indicator | CNXU | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 46.72 |
| Support Level | $7.37 | $9.84 |
| Resistance Level | $10.77 | $10.15 |
| Average True Range (ATR) | 1.28 | 0.13 |
| MACD | 0.25 | 0.01 |
| Stochastic Oscillator | 65.65 | 33.93 |
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.